Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
DuPont (DD) Tops Q2 Earnings & Sales Estimates, Raises FY21 View
by Zacks Equity Research
DuPont (DD) gains on a recovery in key end-markets such as automotive, construction and industrial and sustained strength in semiconductor and smartphones in Q2.
Mosaic's (MOS) Q2 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Mosaic (MOS) benefits from higher year over year prices in the second quarter that offset lower volumes.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours' (CC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Chemours (CC) delivers impressive second-quarter results, led by strong sales growth across all its units backed by global macroeconomic recovery.
Chemours (CC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 34.83% and 9.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours' (CC) second-quarter results are likely to reflect increasing customer adoption of Opteon refrigerants as well as benefit from cost-cutting measures.
Chemours (CC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Chemicals Market Is Evolving and Growing: 8 Picks
by Sejuti Banerjea
The chemical-diversified industry is poised to grow strongly over the next few years, so this is a great time to get some exposure.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Breaks Ground on New Mining Facility in Florida
by Zacks Equity Research
Chemours (CC) expands mining projects in Florida, ensuring environmentally sustainable methods and job creation.
Why Chemours (CC) Stock Might be a Great Pick
by Zacks Equity Research
Chemours (CC) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
This 1 Basic Materials Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks.com featured highlights include: Macy's, Adient, Imperial Oil, Ryder System and The Chemours Co
by Zacks Equity Research
Zacks.com featured highlights include: Macy's, Adient, Imperial Oil, Ryder System and The Chemours Co
5 Top-Ranked Stocks Displaying High Earnings Yield
by Rimmi Singhi
Earnings yield is an important tool for investors with exposure to both stocks and bonds.
Why You Should Add Chemours (CC) Stock to Your Portfolio Now
by Zacks Equity Research
Chemours (CC) benefits from increasing adoption of the Opteon platform and its efforts to reduce costs.
CC or PPG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CC vs. PPG: Which Stock Is the Better Value Option?
Are Investors Undervaluing Chemours (CC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Chemours (CC) Stock a Solid Choice Right Now?
by Zacks Equity Research
Chemours (CC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Strong Demand, Manufacturing Upswing Buoy Chemicals: 5 Top Picks
by Anindya Barman
A strong revival in industrial demand and strengthening manufacturing activities are driving the upturn in the chemical industry. DOW, OLN, UNVR, WLK and CC are good options for investment right now.
Chemours (CC) Stock Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Chemours (CC) is gaining from higher demand for Opteon in mobile applications and cost-cutting measures.
Why Is Chemours (CC) Up 18.5% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours' (CC) Opteon XL41 Selected by Johnson Controls
by Zacks Equity Research
Chemours (CC) has been selected by Johnson Controls to provide Opteon XL41 for the latter's HVAC products to facilitate the phase out of high GWP options.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Chemours (CC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.